| pubmed-article:8353078 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0278846 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:8353078 | lifeskim:mentions | umls-concept:C0085752 | lld:lifeskim |
| pubmed-article:8353078 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8353078 | pubmed:dateCreated | 1993-9-21 | lld:pubmed |
| pubmed-article:8353078 | pubmed:abstractText | Locally advanced malignant thymomas are usually radically resectable in about 60% of stage III but hardly ever in stage IVA. Neoadjuvant chemotherapy followed by surgery could improve both resection rate and curability. Cisplatin containing regimens have repeatedly been found to be highly active in advanced disease, with overall response rates ranging from 80%-90%. | lld:pubmed |
| pubmed-article:8353078 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8353078 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8353078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8353078 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8353078 | pubmed:month | May | lld:pubmed |
| pubmed-article:8353078 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:BerrutiAA | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:BorasioPP | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:DogliottiLL | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:MossettiCC | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:GorzegnoGG | lld:pubmed |
| pubmed-article:8353078 | pubmed:author | pubmed-author:RoncariAA | lld:pubmed |
| pubmed-article:8353078 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8353078 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:8353078 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8353078 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8353078 | pubmed:pagination | 429-31 | lld:pubmed |
| pubmed-article:8353078 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:meshHeading | pubmed-meshheading:8353078-... | lld:pubmed |
| pubmed-article:8353078 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8353078 | pubmed:articleTitle | Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. | lld:pubmed |
| pubmed-article:8353078 | pubmed:affiliation | Department of Clinical and Biological Sciences, University of Torino, Italy. | lld:pubmed |
| pubmed-article:8353078 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8353078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8353078 | lld:pubmed |
